BIOTECH PHARMA SUMMIT

Companion Diagnostics & Biomarkers

26-27 October 2017 | Porto, Portugal

KEY PRACTICAL LEARNING POINTS OF THE SUMMIT

- Learn the recent advances and future perspectives in Companion Diagnostics & Biomarkers
- Understand the key aspects & challenges of Clinical Biomarker development & qualification
- Solutions for clinical development of precision therapies
- Regulatory considerations for Next Generation Sequencing (NGS)
- Main barriers to progression of precision medicine in drug development
- The Role of In Vitro Diagnostics in Successful Precision Medicine Market Access
- Options for biomarker based patient stratification in NON-ONCOLOGY clinical development
- Key trends in targeted and immuno-oncology companion diagnostics
- Overcoming challenges in the global commercialization of novel biomarkers Diagnostic
- Strategies for Cancer Immune Therapies
- Strategic Partnerships for CDx – Challenges and Opportunities

FEATURED SPEAKERS

Anand Subramony, US
Vice President, Novel Product Technologies at MedImmune

Christopher Ung, US
Chief Business Officer at HistoGeneX

Dr. Harry Glorikian, US
CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs

Henrik Winther, SE
Senior Vice President, Precision Diagnostics at Immunovia AB

Dr. Nick Zhang, CN
Chairman and CEO at QIAGEN (Suzhou) Translational Medicine Co. Ltd.

Paul Whittaker, UK
Vice President, Discovery Research at hVIVO

SPEAKERS LIST

Dr. Abdel B Halim, US
VP Translational Medicine, Biomarkers & Diagnostics Celldex Therapeutics

Dr. Alfred Hansel, DE
CEO
at oncgnostics GmbH

Anand Subramony, US
Vice President, Novel Product Technologies at MedImmune

Dr. Ashok Chander, US
CEO
at Cellanyx

Austin Speier, US
Vice President, Emerging Technologies at Precision for Medicine

Christopher Ung, US
Chief Business Officer
at HistoGeneX

Dr. Harry Glorikian, US
CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs

Henrik Winther, SE
Senior Vice President, Precision Diagnostics at Immunovia AB

Dr. Iain D. Miller, UK
Founder
at Healthcare Strategies Group

Jeffrey Jones, US
Executive Vice President, Commercial Operations at SkylineDx

Jürgen Doppke, DE
Director, Business Development at Thermo Fisher Scientific

Dr. Martina Kaufmann, DE
Managing Director at Martina Kaufmann Strategic Consulting

PROGRAM COMMITEE

Dr. Morteza Minaee, US
VP, Regulatory Affairs
at Guardant Health

GUARDANT HEALTH

Dr. Nick Zhang, CN
Chairman and CEO at QIAGEN (Suzhou)
Translational Medicine Co. Ltd.

QIAGEN

Paul Whittaker, UK
Vice President, Discovery
Research at hVIVO

hVIVO
better treatments, faster

Prof. Robert Hawkins, UK
Cancer Research UK Professor
at University of Manchester

MANCHESTER 1824
The University of Manchester



Rohit Nambisan, US
SVP Product Strategy & Partner
Integration at Treato, Product
Advisor at Neurolex Diagnostics

treato NeuroLex

Dr. Stefan Müllner, DE
General Manager & Partner at
Fundamenta Life Science GmbH

fundamenta
LIFE-SCIENCE

Dr. Susanta K. Sarkar, US
President at CadenzaMed LLC
Adjunct Associate Professor
at University of Pennsylvania

Penn

EXPERTS FROM AROUND THE WORLD IN ONE PLACE

The BioTech Pharma Summit is proud to present the Companion Diagnostics & Biomarkers edition. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner.

This year, for the second time, the BioTech Pharma Summit will meet to analyze and tackle the latest and greatest opportunities in the CDx. In this Summit you will learn more about doing partnership and commercialize CDx tests with pharmaceutical and biotech companies.

We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

We sincerely hope you are able to join us for this year's meeting and be part of a new paradigm of precision medicine.

BENEFITS OF ATTENDANCE

The summit is an executive format where case study presentations and panel discussions enable an interactive exchange of ideas and experiences, you will be able to have many networking opportunities with senior peers and get post event follow up offering all documentation from the meeting and re-booking discounts.

WHO SHOULD ATTEND

The BioTech Pharma Summit 2017 is an exclusive event designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

- Companion Diagnostics
- Molecular Diagnostics
- Personalized Healthcare
- Clinical Development
- Regulatory Affairs
- Molecular Diagnostics
- Biomarkers
- Medical Sciences
- Experimental Medicine
- Translational Medicine
- Immunology
- Genomics
- Insurers
- Patient Advocates
- Payers
- Market Access
- Commercialisation
- Oncology
- Non-oncology
- Rare Diseases
- Drug Development
- Research

ABOUT US

EPM Group is a unique company that promotes global summits, conferences, B2B (business-to-business) meetings, seminars, workshops and develops collaborations between all enterprises in order to promote business development in all areas.

New trends, Innovations, Modern technologies, New products, Emerging topics are generated for senior level executives to provide a cutting edge of business information and maximum return of investment for our clients from different areas, such as Pharmaceutical, Renewable Energy, Oil & Gas, Logistics and Supply Chain and Infrastructure.

Our goal is to become a top event company of designing, producing and delivering highly conceptual and fully integrated events.

DAY 1 - CONFERENCE

08:00 ▶ Registration and Welcome Coffee

08:40 ▶ Opening of the BioTech Pharma Summit: Companion Diagnostics & Biomarkers

CDx & Biomakers: Current, Future & Trends

08:50 ▶ **Case Study | Dr. Harry Glorikian, US** - CEO, Sr. Exec., Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs
The changing face of healthcare: dawn of individualized medicine

- Shift to data driven and evidence based system to support value based health and healthcare decisions. Integration of multiplex diagnostics into development programs
- Efficient and effective use of genetic and molecular characterization to shape the way medicine is practiced and the way drugs are approved
- Greater integration of discovery, clinical trials, and ongoing clinical care to transform evidence generation for improved healthcare decisions

09:30 ▶ **Speed Networking |** Innovative approach to maximize networking capabilities through two minute periods, where delegates can meet their peers and exchange business cards before rotating to the next company representative

10:00 ▶ **Case Study | Dr. Martina Kaufmann, DE** - Managing Director at Martina Kaufmann Strategic Consulting
Companion diagnostics – recent advances and future perspectives

- How CDx did evolve
- The evolving regulatory landscape
- The emergence of new technologies, and the development of new concepts.

10:40 ▶ **Morning Coffee and Networking Break**

Progression & Challenges of Precision Medicine

11:10 ▶ **Case Study | Dr. Nick Zhang, CN -** Chairman and CEO at QIAGEN (Suzhou) Translational Medicine Co. Ltd.
Biomarker and CDx--- the first half of Precision Medicine

- Overview of biomarker and CDx
- Our CDx business model and case studies
- Biomarker and CDx development in China

11:50 ▶ **Case Study | Dr. Abdel B Halim, US** - VP Translational Medicine, Biomarkers & Diagnostics Celldex Therapeutics
Main barriers to progression of precision medicine in drug development

- Value of precision medicine and CDx in drug development
- Critical challenges
- Possible mitigations

12:30 ▶ **Case Study | Prof. Robert Hawkins** - Cancer Research UK Professor at University of Manchester
Adoptive cell therapy for cancer using both natural and engineered T-cells

13:00 ▶ **Business Lunch**

Diagnostics & Testing

14:00 ▶ **Case Study | Rohit Nambisan, US** - SVP Product Strategy & Partner Integration at Treato, Product Advisor at Neurolex Diagnostics
Patient Perspectives on Diagnostics & Testing

- Assessing patient perspectives in Diagnostics development & commercialization programs
- Identifying Opportunities and Threats in early development through real world data & patient reported outcomes

CDx & Biomarkers to guide Cancer Immunotherapy

14:40 ▶ **Case Study | Dr. Iain D. Miller, UK** - Founder at Healthcare Strategies Group
Key trends in targeted and immuno-oncology companion diagnostics

- Evolution of high complexity companion / complementary and baseline testing in targeted and immuno-oncology
- Market access for companion diagnostics – emerging global best practices in UK, broader EU and US
- Emerging business models

15:20 ▶ **Case Study | Dr. Alfred Hansel, DE** - CEO at oncgnostics GmbH
Epigenetic markers in cancer diagnostics

- Basics on epigenetic markers
- Identification and diagnostic testing of markers
- The current use of epigenetic markers in diagnostics

16:00 **Coffee & Networking Break**

16:30 **Case Study | Dr. Stefan Müllner, DE** - General Manager & Partner at fundamenta Life Science GmbH
Options for biomarker based patient stratification in NON-ONCOLOGY clinical development

- Current status of biomarkers used in clinical development of novel autoimmune drugs
- Market needs and customer demand
- Health economic aspects of more efficient biomarker based clinical development of new drugs in large indication areas, e.g. metabolism, cardiovascular, neurodegeneration

17:10 **Case Study | Dr. Ashok Chander, US** - CEO, Cellanyx
Personalized Oncology Solutions: Live Cell Behavior

- Understanding the aggressiveness of cancer is the next big challenge in personalized medicine.
- Tumor heterogeneity is a major biological obstacle towards personalized medicine.
- Live Cell Phenotypic Diagnostics on primary biopsy cells is a powerful solution to understanding tumor heterogeneity.
- Emerging clinical evidence support Live Cell Phenotypic Diagnostics as an important addition to genomic technology as well as a potential new technology and class of diagnostics for personalized medicine

18:00 **Panel discussion |** Moderated by the Chairman

- Latest advances in overcoming tumor-induced immune suppression and immune escape
- Standardization of existing assays and approaches
- Clinical trials for cancer immunotherapy: specific features and the role of diagnostics

18:30 **Chairman's Closing Remarks**

19:30 **Gala Dinner |** We have programmed a dinner in one of the finest restaurants of the city of Porto

DAY 2 - CONFERENCE

08:30 Registration and Welcome Coffee

08:50 Opening of the BioTech Pharma Summit: Companion Diagnostics & Biomarkers

Novel Technologies and approaches

09:00 **Case Study | Dr. Susanta K. Sarkar, US** - President at CadenzaMed LLC Adjunct Associate Professor at University of Pennsylvania
Non-invasive Imaging based Companion Diagnostics: A Novel Approach

- Need for companion diagnostics in drug development
- Why Non-invasive Imaging approach: Background
- Impact of Imaging based companion diagnostics

09:40 **Case Study | Anand Subramony, US** - Vice President, Novel Product Technologies at MedImmune
Enabling patient centric medicine

- Novel product development
- Patient centricity
- Digital health
- Controlled release and drug delivery
- Precision medicine

10:20 **Coffee & Networking Break**

10:50 **Case Study | Austin Speier, US** - Vice President, Emerging Technologies at Precision for Medicine
Integrating Digital Medicine into a Biomarker Strategy

- Identifying opportunities to leverage digital medicine in targeted therapeutic strategies
- Understanding and de-risking "digital biomarkers" and other digital medicine development tools
- Practical approaches for integrating digital medicine into clinical studies for therapeutics

CDx & Biomakers: Strategies, Partnerships, Development and Commercialization

11:30 ▶ **Case Study | Christopher Ung, US** - Chief Business Officer at HistoGeneX
Digital Pathology in Immuno-Oncology - A Roadmap for Clinical Development

- Immuno-oncology has catalyzed histopathology applications, such as TIL location and spatial analyses, that benefit from digital pathology.
- Digital Pathology validation models are present for manufacturers and diagnostics but needed for clinical development.
- The rapid evolution of PD-L1 scoring algorithms create an acute need for pathologist training and proficiency. A well-designed training module addresses these needs

12:10 ▶ **Case Study | Paul Whittaker** - Vice President, Discovery Research at hVIVO
Utilising human challenge studies to accelerate the development of new therapies for respiratory disease

- Human models of disease as a way to better understand human pathology
- Disease in motion - the power of clinical and molecular time course data sets and matched clinical samples
- Data mining to accelerate drug target and biomarker discovery

13:00 ▶ **Business Lunch**

CDx & Biomakers: Strategies, Partnerships, Development and Commercialization

14:00 ▶ **Case Study | Jürgen Doppke, DE** - Director, Business Development at Thermo Fisher Scientific
Targeted Next Generation Sequencing Panels for the Rapid Development of CDx in Oncology

- A Universal Diagnostic for solid tumors
- NGS Panels for hematological Cancers
- NGS Panels for Immuno-Oncology Response
- Liquid Biopsy Panels

14:40 ▶ **Case Study | Dr. Morteza Minaee, US** - VP, Regulatory Affairs at Guardant Health
Regulatory considerations for Next Generation Sequencing (NGS)-based circulating tumor DNA (ctDNA) as biomarker candidates into companion diagnostics

- Evolving Regulatory environment for NGS and Cancer Comprehensive Genomic Profiling
- ctDNA assays- Challenges and opportunities
- ctDNA intended uses and indications- A changing model
- Analytical Performance Studies Consideration
- Clinical Validation Considerations
  - Three Alternative Pathways
    - _ Method Comparison Approach
    - _ Retrospective Clinical Bridging Approach
    - _ Prospective patient enrollment Approach

15:20 ▶ **Coffee & Networking Break**

16:50 ▶ **Case Study | Jeffrey Jones, US** - Executive Vice President, Commercial Operations at SkylineDx
Overcoming challenges in the global commercialization of novel biomarkers

- Building a comprehensive market access strategy – develop and validate your opportunity first.
- Generating powerful evidence – start your publication planning early.
- Communicating a compelling value proposition – leveraging an insight-driven commercialization strategy

17:30 ▶ **Case Study | Henrik Winther** - Senior Vice President, Precision Diagnostics at Immunovia AB
Strategic Partnerships for CDx - Challenges and Opportunities

- What is required to become a successful CDx provider?
- What are the major challenges?
- How could these challenges potentially be solved?
- Trusted partnership is key within Rx-CDx development

18:10 ▶ **Panel discussion |** Moderated by the Chairman
Companion Diagnostics Development & Partnering Strategies

18:30 ▶ **Chairman's Closing Remarks and End of Summit**

Speakers Biographies

1

Dr. Abdel B Halim, US

VP Translational Medicine, Biomarkers & Diagnostics Celldex Therapeutics

Celldex therapeutics

Dr Abdel Halim is an internationally-recognized executive with 25+ years of experience in different aspects of biomarkers, precision medicine and IVD; from strategic planning to actualization. He is the VP of Translational Medicine, Biomarker and Diagnostics at Celldex Therapeutics, USA. Before Celldex, Dr. Halim held multiple leadership positions in the pharmaceutical and diagnostic industries. He oversaw the development and validation of assays for 1,000+ biomarkers on different platforms and their applications in 200+ PI-PIV clinical trials and patient managements, and led several CDx programs. Dr. Halim has served on 20+ governmental and public expert panels and advisory groups in the US, Canada and EU, and on 25+ committees to establish guidelines to promote quality in clinical laboratory and diagnostic industries. Abdel has 65+ peer-reviewed publications and approximately 100 presentations including 35+ invited and keynote speeches in national and international meetings.

Dr. Alfred Hansel, DE

CEO
at oncgnostics GmbH

oncgnostics

As CEO Dr. Hansel is responsible for business development at oncgnostics. He has long-lasting experience in project management obtained while working at several universities in Germany and abroad as well as operative experience in industrial product development, sales and marketing. The spin-off of oncgnostics is based on his research as well as works of a project group at the university hospital, which he has led.

Anand Subramony, US

Vice President, Novel Product Technologies at MedImmune

MedImmune

Anand Subramony is Vice President of Novel Product Technologies at MedImmune, the global biological arm of AstraZeneca. In this role, Dr. Subramony heads the function from the CTO office and oversees efforts on digital health and precision medicine. Key focus areas are creating patient centric products that rely on the principles of digital health, connected devices/drug-device combination products and other novel technologies for the diverse portfolio including diagnostics and sensors. Dr. Subramony also focusses in evaluating disruptive delivery technologies in the areas of drug targeting/nanomedicine, and novel biologics. Dr. Subramony in his career has successfully built teams and led projects to product launches. Before his current role, Dr. Subramony was Principal Fellow and Director of the Novel Delivery Technologies & Therapeutics program at the Novartis Institute for BioMedical Research (Cambridge, MA) where he established and managed a high performing cross functional team that led several evaluations with a culture of execution excellence and quick decision making.

Dr. Ashok Chander, US

CEO
at Cellanyx

CELLANYX DIAGNOSTICS

As CEO of Cellanyx Diagnostics, Ashok is currently advancing a novel live cell biopsy-on-a-chip technology. As reported by Boston Business Journal, Urology Today and The Wall Street Journal's Venture Wire, Cellanyx provides a first-in-class live cell phenotypic cancer diagnostic platform to aid clinical decision making and reduce repeat biopsies. The Cellanyx live-cell biomarker platform has potential use in cancer diagnosis, risk stratification and prognostic applications in a wide range of human cancers and as a research tool for biomarker and drug development. Ashok developed Cellanyx's core technology during an academic career researching topics including multidrug resistance and matrix-biology. A Fellow of Startup Leadership Boston, Ashok combines his background in biophysics with expertise in business on project management, operations, team development, entrepreneurship and raising capital. Passionate about translating basic scientific discoveries into therapeutic gains, and engaged in oncology research since 1996, Ashok is exceptionally motivated to create meaningful value for patients, physicians, payers, and investors. In collaboration with Cellanyx's Scientific Advisory Board, Ashok has successfully initiated and currently leads five diagnostic clinical programs.

Speakers Biographies
2

Austin Speier, US
Vice President, Emerging Technologies at Precision for Medicine

Austin is Vice President, Emerging Technologies at Precision for Medicine, where he specializes in the design and execution of to-market clinical and regulatory strategies for innovative, first-in-class diagnostics, digital health and medical device technologies. He has over 10 years of experience supporting innovation in the life sciences and has worked on over 200 diagnostics, software apps, therapeutics and combination products across all clinical areas, with a focus on developing a strong evidence base, managing development risk, and securing product marketing approval. His experience includes both direct support of executive management teams, as well as work with strategic partners and investors to evaluate product opportunities and to guide pre-market clinical and regulatory programs.

Christopher Ung, US
Chief Business Officer at HistoGeneX

Mr. Christopher Ung led the global development and commercialization efforts of HercepTest™ and pharmDx EGFR companion diagnostic assays. He continues to lead and implement global biomarker strategies for drug development and companion diagnostic projects. He has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore, all of which are connected via a digital pathology WSI scanning and analysis platform.
Mr. Ung spends his time working with oncology translational and clinical development teams at pharmaceutical and biotechnology development teams. He regularly speaks and writes on digital pathology applications, multiplex IHC, RNA Sequencing and ensuring that specimens pre-analytics are understood and properly considered. Mr Ung sits on several biotechnology scientific advisory boards and is a committee member of the Digital Pathology Association and the US Chinese Anti-Cancer Alliance.

Dr. Harry Glorikian, US
CEO, Sr. Executive, Board Director, Author, MoneyBall Medicine & Commercialization of Novel IVDs

Harry Glorikian is an influential global business expert with more than three decades of experience building successful ventures in North America, Europe, Asia and the rest of the world. Harry is well known for achievements in life sciences, healthcare, healthcare IT and the convergence of these areas. He is a sought-after speaker, frequently quoted in the media, and regularly asked to assess, influence, and be part of innovative concepts and trends. He holds four US patents in telecommunications, and has others pending. He recently served as an Entrepreneur In Residence to GE Ventures – New Business Creation Group. He serves on the board of GeneNews Ltd. (a molecular diagnostic company). He also serves on the advisory board of Nucelis (a gene-editing industrial biotech company), Evidation Health (a digital health startup launched with support from GE Ventures), and several other companies. He is also a co-founder and an advisory board member of DrawBridge Health (a revolutionary diagnostics startup launched with support from GE Ventures).

Henrik Winther, SE
Senior Vice President, Precision Diagnostics at Immunovia AB

Henrik Winther has been at the forefront of companion diagnostics for over 10 years. He brings solid experiences within R&D, business development, regulatory, manufacturing and commercialization of IVD products. From 2006, Henrik was R&D Director at Dako A/S and spearheaded the design responsibility of their most successful product, the HercepTest CDx assay, and later was Head of Dako Business Development and involved in the acquisition of Dako by Agilent Technologies. From 2013-2017, he continued at Agilent in Santa Barbara, CA, as Vice President and General Manager – as well as head of the R&D function - of the Companion Diagnostics Division, and in addition to scaling up the division, increased revenues significantly through fee-for-service collaborations with pharma and CDx-product releases. Henrik holds a DVM and PhD in cell biology and histology from University of Copenhagen. He has earlier worked as an Associate Professor within cell biology, but during the last 17 years focused on cancer diagnostics.

Speakers Biographies
3

Dr. Iain D. Miller, UK
Founder
at Healthcare Strategies Group

Dr. Iain Miller has extensive international experience in the development of commercial strategy in the precision medicine field. His recent client and broader experience base spans GE Healthcare, Biomerieux, J&J, Philips, Myriad Genetics, Sanofi, Oxford Immunotec, and Abbott Diagnostics, in addition to various SMEs and investor groups. In addition to his 20-year US-based experience, Dr. Miller has worked extensively in the UK and broader EU marketplace, including major market access policy projects with European thought leaders, with a focus on building successful co-development collaborations and commercial strategies in the field of precision oncology. He is also a founding Board member of the European Personalized Medicine Association and sits on the NICE (UK) Technology Appraisal Committee which reviews drugs and companion test products. From his current base in London, UK, Dr. Miller contributes regularly to various policy groups and publishes regularly, including a September, 2016 article "The Emergence of High Complexity Companion Testing for Targeted and Immuno-Oncology" in the Journal Personalized Medicine and several article in 2017 on companion/ complementary market strategy..

Jeffrey Jones, US
Executive Vice President,
Commercial Operations at SkylineDx

Mr. Jones joined SkylineDx as the Executive Vice President, Commercial Operations in August 2015. He brings more than twenty-five years of experience to SkylineDx as a proven commercial leader in the global in-vitro diagnostics industry. With extensive experience in the oncology and laboratory services markets, Jeff has a demonstrated track record of bringing to the global market new and novel technologies, increasing revenues, profitability, and brand awareness. Most recently, Jeff was the Executive Vice President, Global Marketing at Agendia. Previously, he was the Vice President, Global Product Marketing for GE Healthcare's Clarient diagnostic services business. Prior to that, Jeff worked for several Fortune 500 companies to include: Abbott Diagnostics, Bayer Healthcare, and Quest Diagnostics where he held both regional and global positions of increasing responsibility. Jeff received his undergraduate degree from UCLA.

Jürgen Doppke, DE
Director, Business Development
at Thermo Fisher Scientific

Dr. Juergen Doppke, received his PhD from the Ruhr University in Bochum in cooperation with Boehringer Ingelheim. Subsequently he gained 15 Years Experience in various Roles as Sales- and Product Specialist, Field Application Scientist and Product Line Leader for Lab Automation, Research Instrumentation and High Content Screening Products for Companies like Beckman Coulter, Molecular Devices and Perkin Elmer. He joined Thermo Fisher Scientific in 2014 as Director, Business Development Diagnostics Partnering for Central Europe. In his current role he is responsible for partnerships with European Pharma Partners to develop Customized Diagnostics and Companion Diagnostics; leveraging existing IVD platforms with focus on targeted Next Gen Sequencing Panels and Liquid Biopsy for Oncology as well as Immunodiagnostics.

Dr. Martina Kaufmann, DE
Managing Director at Martina
Kaufmann Strategic Consulting

Dr. Martina Kaufmann, Managing Director at Martina Kaufmann Strategic Consulting (www.mk-stracon.com) has 15+ years industry experience in the field of personalized medicine - from biomarker validation, companion diagnostics development to implementation of such products in the market. She served in various roles of increasing responsibility in business and development functions in small biotech/ diagnostic companies as well as in global pharmaceutical & diagnostics corporations (Hoffmann-La Roche AG, Novartis Pharma AG, Novartis Molecular Diagnostics), where she e.g. led the Herceptin® biomarker / companion diagnostics activities and did build up the oncology biomarker group in Basel, respectively. Since April 2012 she is offering her comprehensive and longtime experience as a consultant to an international clientele in both pharma and diagnostics industry. Her services range from strategic concept development to project specific consulting for CDx development under consideration of strategic, scientific, regulatory, operational and commercial aspects.
In addition, she´s contributing to personalized medicine conferences and giving lectures in personalized medicine (ETH Zurich, University of Heidelberg).

Dr. Morteza Minaee, US

VP, Regulatory Affairs
at Guardant Health

GUARDANT HEALTH

Dr. Morteza Minaee has more than 25 years of experience in the FDA-regulated medical devices and global diagnostic industry leading regulatory, quality-systems, and clinical-affairs organizations. He is currently Vice President of Regulatory Affairs at Guardant Health in Red Wood City California. Prior to Guardant Health he served as Senior Director, Regulatory Affairs at Roche leading many FDA clearances in digital pathology applications including breast cancer biomarkers. He also held senior positions in Regulatory, Clinical Affairs, and Quality for companies such as Abbott Molecular and Siemens Healthcare. He holds a doctorate in law and policy from Northeastern University, and MS in administration from Boston University.

Dr. Nick Zhang, CN

Chairman and CEO at QIAGEN (Suzhou)
Translational Medicine Co. Ltd.

QIAGEN

With over 25 years of drug R&D experience and years of experience in translational and diagnostics, Nick is now the board chairman and CEO for QIAGEN (Suzhou) Translational Medicine Co. Ltd. that provides an integrated technology platform for biomarker, companion diagnostics development and clinical testing for precision medicine. Nick started his drug industry career at Pfizer global R&D center after he got his Ph.D degree from University of Cincinnati. During his ten years at Pfizer, he led teams at both Early and Full Development in Pharmaceutical Science, filed 5 INDs/IMPD and 1 NDA/MAA for various dosage forms. Nick represented Pfizer serving on the PRQI working committee (formed among FDA, industry and academia). Before going to US, Nick worked and studied at Chinese Academy of Sciences.

Paul Whittaker, UK

Vice President, Discovery
Research at hVIVO

hVIVO

Currently Vice President, Discovery Research at hVIVO (formerly RetroScreen Virology Ltd) with responsibility for strategic direction and leadership of scientific activities aimed at identifying and developing drug targets and biomarkers for respiratory disease. Previously Unit Head for pre-clinical biomarkers in the Respiratory Disease Area of the Novartis Institutes for Biomedical Research in the UK with experience in a range of activities from target identification and validation, through lead identification and optimisation to biomarker development for clinical trials. Prior to that 14 years as an academic researcher, including 7 years as a Research Lecturer at Southampton University Medical School.

Prof. Robert Hawkins, UK

Cancer Research UK Professor
at University of Manchester

MANCHESTER 1824
The University of Manchester

Robert Hawkins is Cancer Research UK Professor at the University of Manchester and Christie Hospital. In addition to clinical training he was an MRC Research Fellow with Dr Greg Winter and Dr Cesar Milstein at the MRC laboratory of Molecular Biology in Cambridge. His PhD was in antibody engineering and as a Cancer Research UK Senior Clinical Fellow he developed translational research interests in antibody based gene therapy. He was first appointed as a consultant in Cambridge in 1995 and then became Professor of Oncology at the University of Bristol in 1996. In 1998 he moved to the Christie Hospital to become Professor and Director of Medical Oncology. Clinically, He heads a clinical research group undertaking trials renal cancers and also a range of early phase clinical trials of biological agents. He also leads a group undertaking translational research into immunotherapy of cancer with a focus on adoptive cell therapy. In addition, to pre-clinical research he has developed a GMP cell therapy unit to provide clinical grade cell manufacturing – this is now a commercial spinout company (Cellular Therapeutics Ltd). He is/has been the coordinator of several major European Union consortia in this field including the on-going clinical trials project (www.ATTACK-cancer.eu). He has published widely in scientific and clinical journals.



Rohit Nambisan, US

SVP Product Strategy & Partner Integration at Treato, Product Advisor at Neurolex Diagnostics

Rohit's interests lie at the intersection of healthcare and technology. As the SVP, Product Strategy & Partner Integration at Treato, he manages Treato's Product & Innovation portfolio through bridging technological solutions and market need. Additionally, Rohit is the Product Advisor to NeuroLex Dx, a startup developing voice-based diagnostics for mental health disorders.
Prior to these roles, Rohit was the VP & Head of Product at Prognos, a healthcare AI & Data Analytics company focused on diagnostic data solutions for Life Sciences, Payers & Diagnostics companies. Rohit has experience leading product development in Healthcare IT & Big Pharma organizations. Outside of Healthcare & Tech, Rohit is a professional musician & world music band leader, performing and recording throughout the US Northeast. He holds a MS in Engineering & Management from MIT, a MA in Neuroscience from BU, and a BA in Cognitive Science from UC Berkeley.

Dr. Stefan Müllner, DE

General Manager & Partner at Fundamenta Life Science GmbH

Stefan Müllner, a chemist by training, did his Ph.D. thesis in protein biochemistry and postdoc in molecular biology. During his long time as CEO of Protagen AG, he grew the company into the global technology leader in blood based patient stratification to enable novel autoimmune therapy. Before he co-founded Protagen, he worked as Head of Enzyme Technology at Henkel, as well as preclinical pharma research and corporate research at Hoechst, now Sanofi. Stefan has a very broad background and in-depth experience in investments in biotech from his engagements in venture capital and corporate venture capital. He is author and co-author of 48 peer reviewed publications and inventor on 60 patents.

Dr. Susanta K. Sarkar, US

President at CadenzaMed LLC
Adjunct Associate Professor at University of Pennsylvania

Dr. Susanta Sarkar is an internationally recognized medical imaging professional with 28 years of experience in pharmaceutical R&D. He has a strong track record in strategic, scientific and technical leadership in the development and integration of innovative imaging approaches across drug development - from preclinical to clinical and translational studies. He is experienced in developing imaging companion diagnostic agents and has accomplished IND approval for a PET agent from the FDA. Dr. Sarkar is currently the President of CadenzaMed LLC, a company dedicated to providing advanced imaging solutions for precision medicine. He is also an Adjunct Associate Professor at the Department of Radiology, University of Pennsylvania. He was previously Director of Translational/Clinical imaging at Sanofi Oncology and GlaxoSmithKline. Dr. Sarkar serves on the editorial board of Molecular Imaging and Biology and on the Scientific Advisory Board of SibTech Inc. He is the co-chair, Pharma Imaging Network for Therapeutics and Diagnostics and Past Chair, MR in Drug Discovery section, International Society of Magnetic Resonance in Medicine.

REGISTRATION FORM

PACKAGE NAME:

PROMO CODE

①

Name:

Position:

E-mail:

Gala Dinner (Extra 50€/delegate) Yes ☐ No ☐

②

Name:

Position:

E-mail:

Gala Dinner (Extra 50€/delegate) Yes ☐ No ☐

③

Name:

Position:

E-mail:

Gala Dinner (Extra 50€/delegate) Yes ☐ No ☐

Company:

Address:

City: Postcode:

Phone: VAT No:

Date:

Signature:

This booking is invalid without a signature.

▶ To register, please fill the registration form and send to **diogo.ribeiro@epmgroup.org**

Use the promo code "BIOTECH17" till 14th of July and get these discounts:

- Single delegate receives 700€ discount
- Register 3 delegates for the price of 2

* Promo Code is only applicable for the conference package

Conference Package – € 1,895
- 2 days Summit + Master Classes + Interactive Sessions
- Discussion with Industry Experts
- Business Lunches

Academic or Non-Profit Organization Package – € 599
- 2 days Summit + Master Classes + Interactive Sessions
- Discussion with Industry Experts
- Business Lunches

Exhibition Booth – € 3,495
- 3 sq.m. Exhibition Space
- 2 Tickets Standard Package

Keynote Sponsorship – € 4,999
- Speaking slot [20 min]
- 2 Ticket conference package
- Acknowledgement in the opening address
- Logo on conference web-site (with link to company web-site) and on conference proceedings
- 25% discount on extra ticket
- Branding at post-event communication activities

Speaker Sponsorship – € 5,999
- Speaking slot [20 min]
- Company banner displayed at speaker's table
- 3 tickets conference package
- Logo on conference web-site (with link to company web-site) and on brochure
- 50% discount on extra ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities
- Acknowledgement in opening address
- Branding at post-event communication activities

Check other Sponsorship options on the next page

Contact Details

▶ **Diogo Lino Ribeiro**
Project Director, Europe | Porto Office
EM: diogo.ribeiro@epmgroup.org
PH: +351 915 239 640

Terms and Conditions

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

Confirmation
We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

Cancellations
Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

Force Majeure
While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

Copyright

All Prices displayed include VAT @ 23% The VAT amount will be displayed after the payment process and shown on your invoice.

SPONSORSHIP PACKAGES

Exhibition Sponsorship – € 6,999

- 6 m2 Exhibition Space
- 3-Tickets conference Package
- Logo on conference Website (with link to company website)
- Logo on conference brochure

Coffee Break Sponsorship [30 min] – €4,000

- 1-ticket conference package
- Company banner displayed at the coffee area
- Logo on conference program and other marketing channels
- 25% discount on extra delegate ticket
- Branding at the event (rolling logo during breaks)
- Branding at post-event communication activities

Reception Sponsorship – €4,999

- 1-ticket conference package
- Company banner displayed at the event: Reception
- Logo on conference brochure other marketing channels
- Logo on conference web-site (with link to company web-site)
- 25% discount on extra delegate ticket
- Branding at the event (rolling logo during breaks)
- Branding at post-event communication activities

Bronze – €6,999

- Banner display in the exhibit space
- 2-Tickets conference package
- Logo on conference program and other marketing channels (out-reach 15,000 relevant impressions)
- Logo on conference web-site (with link to company web-site) and on conference proceedings
- 1/4 page ad in final program
- 15% discount on extra delegate ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities
- 3m2 Exhibition space

Silver – €8,999

- Opportunity to give a speech at the beginning of conference (10 minutes)
- Acknowledgement in the opening address
- 3-Tickets conference package
- Logo on conference program and other marketing channels (outreach 30,000 relevant impressions)
- Logo on conference web-site (with link to company web-site)
- Logo on conference proceedings
- 1/4 page ad in final program
- 25% discount on extra delegate ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities
- 3m2 Exhibition space



***Printing materials for the booth are included**

Gold – €9,999

- Opportunity to give a speech at the beginning of conference (20 minutes)
- Acknowledgement in the opening address
- 6 m2 exhibition space
- 3 tickets conference package
- Logo on conference program, conference proceedings and other marketing channels (outreach 50,000 relevant impressions)
- Logo on conference web-site (with link to company web-site) and 1/2 page ad in final program
- 30% discount on extra delegate ticket
- Flexible Branding at the event (choose in which occasion you would like to make your branding - leaflets etc.) sponsor provides materials
- List of attendees

Platinum – €11,999

- Opportunity to give a speech at the beginning of conference (40 minutes)
- Opportunity to host a sponsored designed social event (cost taken by sponsor)
- Acknowledgement in the opening address
- Organizing an own seminar/workshop within the conference program
- 8 m2 exhibition space
- 4 tickets conference package
- Logo on conference program, web-site (with link to company web-site), conference proceedings and other marketing channels
- Full page ad in final program
- 50% of discount on extra delegate ticket
- Flexible Branding at the event (choose in which occasion you would like to make your branding - leaflets etc.) sponsor provides materials
- List of attendees

All Prices displayed include VAT @ 23% The VAT amount will be displayed after the payment process and shown on your invoice.